Study Stopped
COVID-19 increased risk of participation
Heart Rate Variability and Emotion Regulation
HRV-ER
Why Does Heart Rate Variability Matter for Emotion Regulation
1 other identifier
interventional
193
1 country
1
Brief Summary
Previous research suggests that heart rate variability (HRV) biofeedback aimed at increasing HRV can reduce anxiety and stress. However, some mental quiescence practices that reduce HRV during the practice sessions also lead to positive emotional outcomes. Thus, it is not obvious that the benefits of HRV-biofeedback accrue due to increasing HRV during the session. An alternative possibility is that the benefits arise from engaging prefrontal control over heart rate. In this study, the investigators will test two possible mechanisms of the effects of HRV on emotional health by comparing two groups. In one group, participants will be asked to engage in daily training to decrease HRV using the HRV biofeedback device. In the other group, participants will be asked to engage in daily training to increase HRV using the HRV biofeedback device. This will allow analyses to pit two possible mechanisms against each other:
- 1.Mechanism 1: engaging prefrontal control over heart rate is the critical factor that allows HRV biofeedback to help improve well-being. In this case, well-being should increase over time in both groups, as both training should engage prefrontal cortex to implement self-directed control over heart rate. Strengthening prefrontal control mechanisms may help improve emotion regulation in everyday life.
- 2.Mechanism 2: increased HRV during the training sessions leads to greater functional connectivity among brain regions associated with emotion regulation during the high HRV state. In this case, improved well-being would be specifically associated with having time each day during which there were very high HRV states, and so improved well-being should be seen only in the group in which participants get biofeedback to increase HRV.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Feb 2018
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 13, 2018
CompletedStudy Start
First participant enrolled
February 14, 2018
CompletedFirst Posted
Study publicly available on registry
March 8, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 13, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
May 5, 2020
CompletedResults Posted
Study results publicly available
May 20, 2025
CompletedJuly 23, 2025
July 1, 2025
2.1 years
February 13, 2018
February 28, 2024
July 11, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
mPFC-right Amygdala Resting-state Functional Connectivity for Younger Adults (ANOVA)
The strength of resting-state functional connectivity was measured by correlation coefficients. Values represent the correlation of BOLD time-series between mPFC and the right amygdala. Higher values indicate greater connectivity.
Time 1 (Baseline), Time 2 (5 weeks)
mPFC-right Amygdala Resting-state Functional Connectivity for Older Adults (ANOVA)
The strength of resting-state functional connectivity was measured by correlation coefficients. Values represent the correlation of BOLD time-series between mPFC and the right amygdala. Higher values indicate greater connectivity.
Time 1 (Baseline), Time 2 (5 weeks)
mPFC-right Amygdala Resting-state Functional Connectivity for Younger Adults (Post-Pre)
The strength of resting-state functional connectivity between mPFC and the right amygdala was measured by correlation coefficients. The difference in functional connectivity between the two time points (Time 2 - Time 1) was calculated. Higher values indicate greater connectivity at Time 2 than Time 1 (or post- than pre-intervention).
Time 1 (Baseline), Time 2 (5 weeks)
mPFC-right Amygdala Resting-state Functional Connectivity for Older Adults (Post-Pre)
The strength of resting-state functional connectivity between mPFC and the right amygdala was measured by correlation coefficients. The difference in functional connectivity between the two time points (Time 2 - Time 1) was calculated. Higher values indicate greater connectivity at Time 2 than Time 1 (or post- than pre-intervention).
Time 1 (Baseline), Time 2 (5 weeks)
Secondary Outcomes (64)
Emotion Regulation in Younger Adults (Behavior)
Time 1 (Baseline), Time 2 (5 weeks)
Emotion Regulation in Older Adults (Behavior)
Time 1 (Baseline), Time 2 (5 weeks)
Left Amygdala BOLD Activity During Emotion Regulation in Younger Adults
Time 1 (Baseline), Time 2 (5 weeks)
Left Amygdala BOLD Activity During Emotion Regulation in Older Adults
Time 1 (Baseline), Time 2 (5 weeks)
Right Amygdala BOLD Activity During Emotion Regulation in Younger Adults
Time 1 (Baseline), Time 2 (5 weeks)
- +59 more secondary outcomes
Other Outcomes (15)
Working Memory for Younger Adults
Time 1 (Baseline), Time 2 (5 weeks)
Working Memory for Older Adults
Time 1 (Baseline), Time 2 (5 weeks)
Processing Speed for Younger Adults
Time 1 (Baseline), Time 2 (5 weeks)
- +12 more other outcomes
Study Arms (2)
HRV-increase group
EXPERIMENTALHalf of the participants will be randomly assigned to this group who will undergo daily practice to increase their heart rate variability (HRV).
HRV-decrease group
EXPERIMENTALHalf of the participants will be randomly assigned to this group who will undergo daily practice to decrease their HRV and heart rate.
Interventions
Participants will be asked to undergo daily practice to regulate (either increase or decrease) HRV for 5 weeks.
Eligibility Criteria
You may qualify if:
- Fluent in English
- Aged between 18-35 for the younger group and aged between 55-80 for the older group
- Scores on TELE indicate no current dementia
- Normal or corrected-to-normal vision and hearing
- People taking antidepressant, anti-anxiety medication and/or attending psychotherapy only if the treatment had been ongoing and unchanged for at least three months
You may not qualify if:
- Have a disorder that would impede performing the HRV biofeedback procedures (i.e., abnormal cardiac rhythm, heart disease including coronary artery disease, angina, and arrhythmia, cardiac pacemaker, stroke, panic attack, cognitive impairment).
- Current practice of any relaxation, biofeedback, or breathing technique.
- Currently taking any psychoactive drugs other than antidepressants or anti-anxiety medications
- No trips that would lead them to miss any of the weekly meetings
- Currently nursing, pregnant, or intend to become pregnant
- Have metals in their body, as this is a scanning requirement
- Have any conditions listed in the MRI Screening form (see below)
- MRI screening
- Cardiac pacemaker
- Implanted cardiac defibrillator
- Aneurysm clip or brain clip
- Carotid artery vascular clamp
- Neurostimulator
- Insulin or infusion pump
- Spinal fusion stimulator
- +31 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Southern California
Los Angeles, California, 90089, United States
Related Publications (2)
Min J, Rouanet J, Martini AC, Nashiro K, Yoo HJ, Porat S, Cho C, Wan J, Cole SW, Head E, Nation DA, Thayer JF, Mather M. Modulating heart rate oscillation affects plasma amyloid beta and tau levels in younger and older adults. Sci Rep. 2023 Mar 9;13(1):3967. doi: 10.1038/s41598-023-30167-0.
PMID: 36894565DERIVEDCho C, Yoo HJ, Min J, Nashiro K, Thayer JF, Lehrer PM, Mather M. Changes in Medial Prefrontal Cortex Mediate Effects of Heart Rate Variability Biofeedback on Positive Emotional Memory Biases. Appl Psychophysiol Biofeedback. 2023 Jun;48(2):135-147. doi: 10.1007/s10484-023-09579-1. Epub 2023 Jan 20.
PMID: 36658380DERIVED
Results Point of Contact
- Title
- Dr. Mara Mather
- Organization
- University of Southern California
Study Officials
- PRINCIPAL INVESTIGATOR
Mara Mather, PhD
University of Southern California
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Gerontology and Psychology
Study Record Dates
First Submitted
February 13, 2018
First Posted
March 8, 2018
Study Start
February 14, 2018
Primary Completion
March 13, 2020
Study Completion
May 5, 2020
Last Updated
July 23, 2025
Results First Posted
May 20, 2025
Record last verified: 2025-07